Skip to main content

Defendants Named in The GDD Litigation Oppose Centralization

Defendants Named in The GDD Litigation Oppose Centralization

Defendants Named in The GDD Litigation Oppose Centralization

Introduction

Gauging the growing number of cases, a group of plaintiffs involved in the Linear Gadolinium-based Contrast Agents (GBCA) lawsuits filed a petition on July 31 before the U.S. Judicial Panel requesting for a multi-district litigation creation, on the grounds of easing coordinated pretrial proceedings, reducing duplicative discovery into common issues, and serving the convenience of witnesses, parties and the judicial system. The Northern District of California was requested by the plaintiffs as the preferred venue for centralization.

In response, an opposition was filed by six manufacturers, named as defendants in the litigation: Bayer, GE Healthcare, Bracco Diagnostics, Mallinckrodt Inc., Guerbet LLC and Liebel-Flarsheim Company, and McKesson Corp. A small pool of cases, diverse manufacturers and products, selection and case eligibility criteria not well defined were a few reasons stated for not agreeing with the creation of the MDL. Moreover, the defendants stated the alleged injuries fall under a broad category which would not be justified by placing under one umbrella of “gadolinium deposition disease (GDD).”

The U.S. JPML will hear the oral arguments on September 27, at the Phillip Burton U.S. Courthouse in San Francisco.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

NC to Get $150M to Boost Opioid Treatment, Recovery

Categories: Opioids

North Carolina will receive an additional $150 million from Purdue Pharma and the Sackler family as part of a national $7.4 billion settlement related to the opioid

SRI Gets FDA OK for High-Dose Naloxone Trial

Categories: Opioids

SRI has received authorization from the U.S. Food and Drug Administration (FDA) to begin Phase 1 clinical trials of a new, high-dose injectable naloxone formulation.

The approval was granted under an Investigational New Drug (IND)…

Spokane County to Get $5M in New Opioid Settlement

Categories: Opioids

Jurisdictions within Spokane County are set to receive nearly $4.7 million as part of a sweeping $7.4 billion nationwide settlement with Purdue Pharma and its owners, the Sackler family.

The agreement addresses the company’s role in fueling…

✍️ FREE—3000 Pages Medical Record Review Trial!                
No Contract. No Risk—Fully Customized, Free!

Only 10 Firms Accepted—Offer Ends June 30!